Thus, biochemical and therapeutic outcomes for CuII(atsm) indicate the compound’s ability to improve Cu bioavailability to SOD1 may contribute, at least in part, to its therapeutic activity in mutant SOD1 mouse models of ALS. Here, SOD1 is linked to amyotrophic lateral sclerosis.